On November 19, 2025, Beijing StoneWise Technology Co., Ltd. announced the official launch of a collaboration with Shenzhen Chipscreen Biosciences Co., Ltd. (Stock Code: 688321.SH) based on the MolVado AI 3D Molecular Generation and Small Molecule Drug Design Platform. Under the collaboration agreement, StoneWise will provide Chipscreen Biosciences with an engineering-oriented AI solution comprising a molecular generation model, a suite of AIDD (AI-aided Drug Discovery) computational tools, and a computing infrastructure to support its exploration and optimization efforts in the small molecule drug R&D phase. As a pioneer in China's original innovative drug sector, Chipscreen Biosciences brings together a team of top-tier scientists with extensive experience in relevant fields. Leveraging an integrated technology platform combining A...

This content is reprinted from "Tianjin Development Zone Technology" | StoneWise: We would like to express our gratitude to the Science and Technology Bureau of Tianjin Binhai New Area and the Tianjin International Joint Academy of Biomedicine for their meticulous organization and invitation, as well as the wonderful sharing and valuable suggestions from all participants! StoneWise has been deeply engaged in the field of AI molecular generation for many years, accumulating solid practical experience and mature methodologies in model construction, technology iteration, and implementation operations. We sincerely welcome industry peers to establish in-depth connections with us, deepen cooperation around customized model development, co-creation of innovative needs, and other directions, work together to address R&D pain points, and jointly promote the innovat...

Recently, the company was invited to participate in the compilation of the industry blue book by Frost & Sullivan, a world-renowned growth consulting firm. This signifies that the company's technical accumulation and industry insights in the field of AI-driven innovative drug R&D have been highly recognized by international authoritative institutions. The blue book will showcase our technological breakthroughs in multiple projects as an industry benchmark case — such as the practical experience of rapidly discovering privileged scaffolds through the AI platform, helping partners shorten R&D cycles and improve druggability success rates. It aims to provide actionable technical pathways and commercialization references for the industry. Recommended Reading   Scan the QR code below to access the report  ...

On September 18, HUAWEI CONNECT 2025, themed "Elevating Industry Intelligence," kicked off grandly in Shanghai. Gathering global industry leaders, technology pioneers, and ecosystem partners from Huawei, the event aimed to explore new paths for intelligent technology to empower industrial upgrading. As a strategic partner of Huawei in the biopharmaceutical sector, Beijing StoneWise Technology Co., Ltd. (hereinafter referred to as "StoneWise") was invited to deliver a keynote speech, sharing cutting-edge explorations and practical experiences in AI-driven novel drug research and development (R&D).   Small-molecule drug R&D enterprises are grappling with industry challenges of rising costs and shrinking margins. Under the traditional R&D model, issues such as a glut of Me-too drugs and lengthy development cycles have become key bot...

AI Reconstructs Drug Discovery: The Transformation from Theoretical Breakthrough to Clinical Value | [July 9th AI Half-Month Talk] Grand Launch   Highlight 01 Paradigm Shift in AI-Driven End-to-End Drug Discovery: From "Tool Empowerment" to "System Reconstruction"   02 Hardcore Closed Loop of "Virtual → Real": The "Triathlon" of Data, Algorithm, and Validation   03 Roundtable Debate: Is AI More Prone to Achieving "me-better" Optimization? Or Can It Spur "first-in-class" or Even "first-in-human" Original Innovation?     AI Half-Month Talk [Issue 9] With the rapid development of Artificial Intelligence (AI) technology, its application in drug research and development is gradually moving from concept to practice. AI not only accelerates early target identification and high-throughput virtu...

Stonewise Debuts at AIBC2025, Focusing on Two Core Challenges of Molecular Generation Models: Data and Evaluation   From June 12 to 13, 2025, the 2025 Artificial Intelligence and Biomedical Ecosystem Conference (AIBC2025) was successfully held in Shanghai. The conference gathered numerous renowned experts and scholars from the academic and industrial sectors at home and abroad to jointly discuss the cutting-edge progress and application practices of Artificial Intelligence (AI) technology in the biomedical field. Dr. Huang Bo, Vice President of R&D at Stonewise, was invited to attend and delivered a keynote speech on the topic of "AI-driven Design of Small Molecule Drugs".   In his speech on the afternoon of June 13, Dr. Huang Bo, with the title "Multimodal AI Generation Model Integrating Experimental Electron Dens...

On June 13, 2025, Beijing StoneWise Technology Co., Ltd. (hereinafter referred to as "StoneWise") announced the first patient dosing of SWA1211 tablets—an independently developed Hematopoietic Progenitor Kinase 1 (HPK1) inhibitor—at Shanghai East Hospital. This marks the official initiation of the Phase I clinical study evaluating the drug for advanced solid tumors.   In March 2025, SWA1211 tablets simultaneously obtained clinical trial approvals from China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). Co-led by Professor Guo Ye from Shanghai East Hospital and Professor Wang Hongxia from Fudan University Shanghai Cancer Center, the study aims to assess the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of SWA1211 tablets in patien...

First Release: Electron Density Based 3D Molecular Generation and Binding Mode   Stonewise® will be presenting during the American Chemistry Society (ACS) fall meeting will taking place August 22-26. Four presentations (2 poster presentations and 2 oral presentations) from Stonewise have been accepted by ACS. Presentations will discuss the creative use of astronomical amount of electron density data in PDB database for model training, as well as electron density based 3D molecular generation and binding mode, which are believed to be the first time in the industry. For further details, please join us in the event for discussion. The presentations are scheduled as below: Oral Presentation 1: Achieving quantum mechanics level quantification of noncovalent interactions in protein-ligand complex with limited-time cost by using machine learning model ...